NASDAQ:HTGM HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free HTGM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$5.01▼$6.8052-Week Range N/AVolume773,040 shsAverage Volume294,806 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get HTG Molecular Diagnostics alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About HTG Molecular Diagnostics Stock (NASDAQ:HTGM)HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). HTGM Stock News HeadlinesMarch 30, 2024 | seekingalpha.comHTGMQ HTG Molecular Diagnostics, Inc.January 4, 2024 | morningstar.comHTG Molecular Diagnostics Inc HTGMQApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.September 26, 2023 | uk.investing.comHTG Molecular Diagnostics Inc (HTGMQ)August 26, 2023 | benzinga.comMolecular Diagnostics Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key PlayersJune 6, 2023 | msn.comHTG Molecular stock tanks in wake of Chapter 11 bankruptcy filingJune 6, 2023 | finance.yahoo.comWhy Are HTG Molecular Diagnostics Shares Plunging TodayJune 6, 2023 | investorplace.comWhy Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.May 18, 2023 | finance.yahoo.comHTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International ConventionMay 16, 2023 | finance.yahoo.comHTG Highlights the Advantages of Its Drug Discovery EngineMay 11, 2023 | finanznachrichten.deHTG Molecular Diagnostics, Inc.: HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsMay 10, 2023 | finance.yahoo.comHTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business HighlightsApril 25, 2023 | finance.yahoo.comHTG Provides Update on Drug Discovery Partnering InitiativeApril 19, 2023 | msn.comHC Wainwright & Co. Reiterates HTG Molecular Diagnostics (HTGM) Buy RecommendationApril 18, 2023 | finance.yahoo.comHTG Announces Key First Quarter Milestone Achievements for Drug DiscoveryApril 6, 2023 | finance.yahoo.comHTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19April 2, 2023 | finance.yahoo.comHTG Molecular Diagnostics Full Year 2022 Earnings: EPS Misses ExpectationsMarch 24, 2023 | msn.comWhy Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving PremarketJanuary 25, 2023 | seekingalpha.comHTGM HTG Molecular Diagnostics, Inc.January 9, 2023 | finance.yahoo.comHTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access EventJanuary 6, 2023 | msn.comHTG Molecular Diagnostics expects FY22 revenue above consensusJanuary 6, 2023 | ca.finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsJanuary 6, 2023 | finance.yahoo.comHTG Announces Certain Preliminary 2022 Unaudited Financial ResultsDecember 30, 2022 | bizjournals.comHTG Molecular Diagnostics of Tucson raises $10M in public offeringDecember 29, 2022 | msn.comPeering Into HTG Molecular Diagnostics's Recent Short InterestDecember 28, 2022 | finance.yahoo.comHTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast SeriesSee More Headlines Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:HTGM CUSIPN/A CIK1169987 Webwww.htgmolecular.com Phone(520) 547-2827Fax520-547-2837Employees84Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,590,000.00 Net Margins-324.25% Pretax Margin-324.05% Return on Equity45.52% Return on Assets8.93% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.30 Sales & Book Value Annual Sales$6.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / BookN/AMiscellaneous Outstanding Shares2,210,000Free Float2,156,000Market CapN/A OptionableOptionable Beta0.99 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesJohn L. LubniewskiPresident, Chief Executive Officer & DirectorShaun D. McMeansCFO, Secretary, Treasurer & SVP-AdministrationByron T. LawsonChief Commercial Officer & Senior Vice PresidentLaura L. GodlewskiChief Accounting Officer & Vice President-FinanceSam M. RuaSenior VP-Regulatory Affairs & Quality SystemsKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInsidersStephen BaratSold 888 sharesTotal: $710.40 ($0.80/share) HTGM Stock Analysis - Frequently Asked Questions How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) posted its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.60). The medical research company earned $2.52 million during the quarter, compared to analysts' expectations of $2.90 million. HTG Molecular Diagnostics had a negative net margin of 324.25% and a positive trailing twelve-month return on equity of 45.52%. During the same period in the previous year, the company earned ($1.05) earnings per share. What is Tim (TJ) Johnson's approval rating as HTG Molecular Diagnostics' CEO? 11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD). When did HTG Molecular Diagnostics IPO? HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. This page (NASDAQ:HTGM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HTG Molecular Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
